JP2007505873A - チロシンキナーゼ阻害剤としてのキナゾリン誘導体 - Google Patents

チロシンキナーゼ阻害剤としてのキナゾリン誘導体 Download PDF

Info

Publication number
JP2007505873A
JP2007505873A JP2006526684A JP2006526684A JP2007505873A JP 2007505873 A JP2007505873 A JP 2007505873A JP 2006526684 A JP2006526684 A JP 2006526684A JP 2006526684 A JP2006526684 A JP 2006526684A JP 2007505873 A JP2007505873 A JP 2007505873A
Authority
JP
Japan
Prior art keywords
alkyl
formula
group
amino
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505873A5 (enExample
Inventor
ブラッドベリー，ロバート・ヒュー
ヘンネキン，ローラン・フランソワ・アンドレ
ケトル，ジェイソン・グラント
バーラーム，ベルナルド・クリストプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007505873A publication Critical patent/JP2007505873A/ja
Publication of JP2007505873A5 publication Critical patent/JP2007505873A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006526684A 2003-09-16 2004-09-14 チロシンキナーゼ阻害剤としてのキナゾリン誘導体 Pending JP2007505873A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292279 2003-09-16
PCT/GB2004/003931 WO2005026151A1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2007505873A true JP2007505873A (ja) 2007-03-15
JP2007505873A5 JP2007505873A5 (enExample) 2007-11-01

Family

ID=34307005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526684A Pending JP2007505873A (ja) 2003-09-16 2004-09-14 チロシンキナーゼ阻害剤としてのキナゾリン誘導体

Country Status (12)

Country Link
US (1) US20070032508A1 (enExample)
EP (1) EP1664028A1 (enExample)
JP (1) JP2007505873A (enExample)
CN (1) CN1882573A (enExample)
AU (1) AU2004272350A1 (enExample)
BR (1) BRPI0414447A (enExample)
CA (1) CA2539022A1 (enExample)
IL (1) IL174258A0 (enExample)
MX (1) MXPA06002963A (enExample)
NO (1) NO20061321L (enExample)
WO (1) WO2005026151A1 (enExample)
ZA (1) ZA200602190B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505878A (ja) * 2003-09-19 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2010529115A (ja) * 2007-06-05 2010-08-26 ハンミ ファーム． シーオー．， エルティーディー． 癌細胞成長抑制用新規アミド誘導体
JP2021500350A (ja) * 2017-10-18 2021-01-07 スペクトラム ファーマシューティカルズ インコーポレイテッド 変異体ｅｇｆｒファミリーチロシンキナーゼの阻害剤

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
AU2004272346A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) * 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
EP1904458A1 (de) * 2005-07-04 2008-04-02 Boehringer Ingelheim International GmbH Verfahren zur herstellung von chinazolinonderivaten
CA2619037A1 (en) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
EP1957499A1 (en) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
EP2079739A2 (en) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
CN105153047A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
CN105153046A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 双卤素取代的乙氧基苯并喹唑啉类酪氨酸激酶抑制剂及用途
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
WO2022105908A1 (zh) * 2020-11-23 2022-05-27 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
EP4267137A4 (en) * 2020-12-22 2024-11-06 Enliven Inc. HETEROARYL-LACTAM-FUSION PYRIMIDINE DERIVATIVES AS ERBB2 INHIBITORS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000504713A (ja) * 1996-02-14 2000-04-18 ゼネカ・リミテッド キナゾリン化合物
JP2002539199A (ja) * 1999-03-15 2002-11-19 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 二環式複素環化合物、その化合物を含む医薬組成物、及び製法
WO2003040109A2 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003040108A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003082290A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren
WO2005026152A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as antitumor agents

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2216169C (en) * 1996-01-31 2007-01-23 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2361174C (en) * 1999-02-27 2009-10-27 Boehringer Ingelheim Pharma Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
AU2004272346A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) * 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000504713A (ja) * 1996-02-14 2000-04-18 ゼネカ・リミテッド キナゾリン化合物
JP2002539199A (ja) * 1999-03-15 2002-11-19 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 二環式複素環化合物、その化合物を含む医薬組成物、及び製法
WO2003040109A2 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003040108A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003082290A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren
WO2005026152A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as antitumor agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. １３, JPN6010053450, 24 February 2003 (2003-02-24), pages 637 - 640, ISSN: 0001730436 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505878A (ja) * 2003-09-19 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2010529115A (ja) * 2007-06-05 2010-08-26 ハンミ ファーム． シーオー．， エルティーディー． 癌細胞成長抑制用新規アミド誘導体
JP2021500350A (ja) * 2017-10-18 2021-01-07 スペクトラム ファーマシューティカルズ インコーポレイテッド 変異体ｅｇｆｒファミリーチロシンキナーゼの阻害剤

Also Published As

Publication number Publication date
CA2539022A1 (en) 2005-03-24
ZA200602190B (en) 2007-09-26
US20070032508A1 (en) 2007-02-08
BRPI0414447A (pt) 2006-11-14
CN1882573A (zh) 2006-12-20
IL174258A0 (en) 2006-08-01
EP1664028A1 (en) 2006-06-07
AU2004272350A1 (en) 2005-03-24
WO2005026151A1 (en) 2005-03-24
MXPA06002963A (es) 2006-06-14
NO20061321L (no) 2006-04-26

Similar Documents

Publication Publication Date Title
JP2007505873A (ja) チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7569577B2 (en) Quinazoline derivatives as tyrosine kinase inhibitors
US7838530B2 (en) Quinazoline derivatives as antiproliferative agents
EP1667996B1 (en) Quinazoline derivatives
US20070015743A1 (en) Quinazoline derivatives as antitumor agents
US20070232607A1 (en) Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
EP1660479A1 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
US7625908B2 (en) Quinazoline derivatives
EP1670786A1 (en) Quinazoline derivatives
KR101244524B1 (ko) 티로신 키나제 억제제로서의 퀴나졸린 유도체
KR20070023630A (ko) 티로신 키나제 억제제로서의 퀴나졸린 유도체
KR20070023629A (ko) 항종양제로서의 퀴나졸린 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110225